Effector Therapeutics Stock Cash Per Share
| EFTRDelisted Stock | USD 0.13 0.03 30.00% |
Effector Therapeutics fundamentals help investors to digest information that contributes to Effector Therapeutics' financial success or failures. It also enables traders to predict the movement of Effector Stock. The fundamental analysis module provides a way to measure Effector Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Effector Therapeutics stock.
Effector |
Effector Therapeutics Company Cash Per Share Analysis
Effector Therapeutics' Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current Effector Therapeutics Cash Per Share | 0.99 X |
Most of Effector Therapeutics' fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Effector Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
CompetitionIn accordance with the recently published financial statements, Effector Therapeutics has a Cash Per Share of 0.99 times. This is 77.24% lower than that of the Biotechnology sector and 77.14% lower than that of the Health Care industry. The cash per share for all United States stocks is 80.24% higher than that of the company.
Effector Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Effector Therapeutics' direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Effector Therapeutics could also be used in its relative valuation, which is a method of valuing Effector Therapeutics by comparing valuation metrics of similar companies.Effector Therapeutics is currently under evaluation in cash per share category among its peers.
Effector Fundamentals
| Return On Equity | -9.47 | ||||
| Return On Asset | -0.83 | ||||
| Current Valuation | (4.52 M) | ||||
| Shares Outstanding | 4.7 M | ||||
| Shares Owned By Insiders | 2.90 % | ||||
| Shares Owned By Institutions | 23.71 % | ||||
| Number Of Shares Shorted | 91.62 K | ||||
| Price To Earning | 1.03 X | ||||
| Price To Book | 13.38 X | ||||
| Price To Sales | 69.65 X | ||||
| Gross Profit | (19.76 M) | ||||
| EBITDA | (33.73 M) | ||||
| Net Income | (35.81 M) | ||||
| Cash And Equivalents | 41.04 M | ||||
| Cash Per Share | 0.99 X | ||||
| Total Debt | 19.45 M | ||||
| Debt To Equity | 1.03 % | ||||
| Current Ratio | 1.79 X | ||||
| Book Value Per Share | 0.21 X | ||||
| Cash Flow From Operations | (29.55 M) | ||||
| Short Ratio | 0.97 X | ||||
| Earnings Per Share | (12.57) X | ||||
| Target Price | 11.0 | ||||
| Number Of Employees | 14 | ||||
| Beta | 0.83 | ||||
| Market Capitalization | 846.79 K | ||||
| Total Asset | 20.54 M | ||||
| Retained Earnings | (179.38 M) | ||||
| Working Capital | (5.96 M) | ||||
| Net Asset | 20.54 M |
About Effector Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Effector Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Effector Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Effector Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Effector Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Effector Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Effector Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Effector Stock
Moving against Effector Stock
| 0.39 | VERA | Vera Therapeutics | PairCorr |
| 0.33 | VCYT | Veracyte | PairCorr |
| 0.32 | DMAC | DiaMedica Therapeutics | PairCorr |
| 0.32 | DRUG | Bright Minds Biosciences | PairCorr |
The ability to find closely correlated positions to Effector Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Effector Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Effector Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Effector Therapeutics to buy it.
The correlation of Effector Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Effector Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Effector Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Effector Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Other Consideration for investing in Effector Stock
If you are still planning to invest in Effector Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Effector Therapeutics' history and understand the potential risks before investing.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |